Article Sidebar
Views pdf: 6
A STUDY ON SERUM NESFATIN-1 CONCENTRATION IN TYPE 2 DIABETIC MELLITUS PATIENTS
Main Article Content
Abstract
Introduction: Nesfatin-1 is an adipocytokin (APC) secreted by many organs in the body, affecting many factors related to the pathogenesis of type 2 diabetes mellitus (T2DM). Nesfatin-1 levels may change in patients with T2DM. Objective: To investigate serum nesfatin-1 levels in patients with T2DM and find out the relationship between nesfatin-1 levels and some clinical and subclinical characteristics in the patients. Subjects and methods: 214 participants were enrolled in the study divided into 2 groups, of which 75 healthy individuals, without hyperglycemia, belonged to the control group, were used to determine the reference range of serum nesfatin-1 levels. The study group included 139 patients who were diagnosed with T2DM for the first time or have been undergoing the treatment. The participants were collected at Hospital 198 - Ministry of Public Security. Serum nesfatin-1 levels were quantified using nesfatin-1 ELISA Kit from BioVendor on the DAX 800 ELISA machine at the Department of Pathophysiology - Vietnam Military Medical University. Unit of measurement: ng/ml. Results: Serum nesfatin-1 levels in the T2DM patients were significantly lower than the reference range [0.2 (0.2-0.3) versus 0.2 (0.2-0.4) ) ng/ml; p<0.001]. The proportions of T2DM patients with decreased, normal and increased nesfatin-1 levels were 49,6%; 45,3% and 5,1%, respectively. Serum nesfatin-1 levels statistically significantly related to time of disease detection, body mass index (BMI), hypertension, but were not statistically significantly related to gender, age group, waist/hip ratio, blood lipid disorders and HbA1c. Conclusion: Nesfatin-1 is an APC with various effects. Nesfatin-1 level can alter with a decreasing trend in metabolic diseases including T2DM.
Article Details
Keywords
type 2 diabetic mellitus, adipocytokin, nesfatin-1
References
2. Qing-Chun Li, Hai-Yan Wang, Xi Chen, et al. (2010), “Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related flunctuation of nesfatin-1 level in normal humans”. Regulatory Peptides, 159; pp. 72-77.
3. Kangkang Huang, Yunlai Liang, Kun Wang, et al. (2022), “Influence of circulating nesfatin-1, GSH and SOD on insulin secretion in the development of T2DM”. Frontiers in Public Health, 10.3389; pp. 1-10.
4. Baydaa Ahmed Abed, Layla Othman Farhan, Ashgan Slman Dawood (2023), “Relationship between serum Nesfatin-1, Adiponectin, Resistin Concentration, and Obesity with Type 2 Diabetes Mellitus”. Baghdad Science Journal, 10.21123.
5. Shimei Ding, Wei Qu, Shuangsuo Dang, et al. (2015), “Serum Nesfatin-1 is Reduced in Type 2 Diabetes Mellitus Patients with Peripheral Arterial Disease”. Med Sci Monit., 21; pp. 987-991.
6. Israa Khalil Ibrahim Al-Yassiri, Fadhil Jawad Al-Tuma, Maher Abbood Mukheef, et al. (2023), “Association between Nesfatin-1 Levels and C-Peptide in Sera of Obese/Non-Obese Type 2 Diabetic Women”. J Contempt Med Sci, Volume 9, Number 1; pp. 56-62.
7. Ayhan Abaci, Gonul Catli, Ahmet Anil, et al. (2013), “The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children”. Pediatric Diabetes, 14; pp. 189-195.
8. S. Mirakhor Samani, H. Ghasemi, K. Rezaei Bookani, et al. (2019), “Serum nesfatin -1 level in healthy subjects with weight-related abnormalities and newly diagnosed patients with type 2 diabetes mellitus; A case-control study”. Acta Endocrinol, 15 (1); pp. 69-73.